Sensei Biotherapeutics Inc Trading Halted
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy SNSE?
Sensei Biotherapeutics Inc trading halted, volatility trading pause
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNSE
About SNSE
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. The Company's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The Company is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sensei Biotherapeutics Grants Stock Options to New Employees
- Stock Option Grants: On February 19, 2026, Sensei Biotherapeutics granted stock options for a total of 2,319,893 shares to 17 new employees, including 1,239,305 shares to COO Anand Parikh, aimed at attracting talent and enhancing the company's competitive edge.
- Exercise Price: The options have an exercise price of $27.22, matching the closing price of Sensei's common stock on the grant date, ensuring that employees can receive fair returns when the company performs well.
- Vesting Schedule: The vesting schedule allows for 25% of the options to vest on the first anniversary of the grant, with the remaining shares vesting monthly over three years, designed to incentivize long-term employee retention and contributions to the company's growth.
- Company Overview: Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer, currently advancing its PIKTOR program in clinical trials and completing a Phase 1/2 trial of solnerstotug for patients with advanced solid tumors, showcasing its innovative potential in the biotech sector.
See More
Sensei Biotherapeutics Secures $200 Million Financing and Acquires Faeth
- Financing Milestone: Sensei Biotherapeutics successfully secured approximately $200 million in private placement financing, with plans to allocate most of the funds towards advancing PIKTOR, including topline results from an ongoing Phase 2 trial expected by the end of 2026, thereby enhancing its competitive edge in oncology.
- Acquisition Impact: By acquiring Faeth Therapeutics, Sensei bolstered its oncology pipeline, with PIKTOR designed as an all-oral drug combination that simultaneously inhibits PI3K-alpha and mTORC1/2, which is anticipated to improve efficacy and tolerability, further solidifying the company's position in the cancer treatment market.
- Stock Price Reaction: Shares of Sensei surged over 200% following the acquisition announcement, reaching their highest level since May 2024 and recording the largest intraday gains in history, indicating strong market confidence in its drug development prospects.
- Market Sentiment Shift: On Stocktwits, retail sentiment flipped from 'bearish' to 'extremely bullish', with many users predicting further stock price increases, reflecting optimistic expectations for Sensei's future performance and driving heightened trading activity.
See More
U.S. Stocks Rise, Nasdaq Gains Over 1%
- Market Performance: U.S. stocks broadly rose on Wednesday, with the Nasdaq Composite gaining over 1% and the Dow up 0.57% to close at 49,814.98, indicating positive market sentiment and increased investor confidence.
- Sector Dynamics: Energy stocks rose by 1.6% on Wednesday, reflecting optimistic expectations for energy demand, while real estate stocks fell by 1.2% on Tuesday, highlighting challenges faced by the sector amid market uncertainties.
- Durable Goods Orders: U.S. durable goods orders fell by 1.4% month-over-month in December, contrasting sharply with a revised 5.4% gain in November, suggesting a potential slowdown in economic growth that could impact future consumer and investment decisions.
- Commodity Markets: Oil prices increased by 4.2% to $64.93 per barrel, gold rose by 2.3% to $5,020.40, and silver climbed 6.2% to $78.120, indicating a rising demand for commodities as investors seek safe-haven assets.
See More
Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M
- Stock Surge: Shares of Sensei Biotherapeutics (SNSE) surged on Wednesday following the announcement of its acquisition of cancer drug developer Faeth Therapeutics, reflecting strong market confidence in the deal and boosting investor sentiment.
- Acquisition Details: The acquisition adds Faeth's oral cancer therapy PIKTOR to Sensei's pipeline, which is expected to provide new revenue growth opportunities for the company, particularly in the competitive cancer treatment market.
- Funding Strategy: Concurrently, the company announced a private placement seeking approximately $200 million through the issuance of Series B non-voting convertible preferred stock, with major investors including RA Capital Management, ensuring robust funding for future R&D initiatives.
- R&D Advancement: Sensei plans to utilize the proceeds to advance PIKTOR through multiple catalysts expected by year-end, including a topline readout from a mid-stage trial in endometrial cancer and the initiation of an early-stage trial in breast cancer, demonstrating the company's strategic focus in oncology.
See More
U.S. Stocks Rise in Morning Trading, Dow Up Approximately 100 Points
- Market Performance: U.S. stocks opened higher on Wednesday, with the Dow Jones index gaining approximately 100 points, or 0.21%, reaching 49,637.82, indicating positive market sentiment.
- Sector Dynamics: Energy shares rose by 1.3% on Wednesday, while real estate stocks fell by 0.8%, reflecting a divergence in performance across different sectors.
- Company Earnings: Analog Devices Inc reported first-quarter earnings of $2.46 per share, exceeding analyst expectations of $2.31, with quarterly sales of $3.16 billion also surpassing the forecast of $3.117 billion, showcasing the company's strong financial performance.
- Commodity Markets: On Wednesday, oil prices increased by 2.9% to $64.13 per barrel, gold rose by 1.8% to $4,994.30, and silver climbed 5% to $77.235, indicating heightened activity in the commodities market.
See More
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
See More
Sensei Biotherapeutics Grants Stock Options to New Employees
- Stock Option Grants: On February 19, 2026, Sensei Biotherapeutics granted stock options for a total of 2,319,893 shares to 17 new employees, including 1,239,305 shares to COO Anand Parikh, aimed at attracting talent and enhancing the company's competitive edge.
- Exercise Price: The options have an exercise price of $27.22, matching the closing price of Sensei's common stock on the grant date, ensuring that employees can receive fair returns when the company performs well.
- Vesting Schedule: The vesting schedule allows for 25% of the options to vest on the first anniversary of the grant, with the remaining shares vesting monthly over three years, designed to incentivize long-term employee retention and contributions to the company's growth.
- Company Overview: Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer, currently advancing its PIKTOR program in clinical trials and completing a Phase 1/2 trial of solnerstotug for patients with advanced solid tumors, showcasing its innovative potential in the biotech sector.
See More
Sensei Biotherapeutics Secures $200 Million Financing and Acquires Faeth
- Financing Milestone: Sensei Biotherapeutics successfully secured approximately $200 million in private placement financing, with plans to allocate most of the funds towards advancing PIKTOR, including topline results from an ongoing Phase 2 trial expected by the end of 2026, thereby enhancing its competitive edge in oncology.
- Acquisition Impact: By acquiring Faeth Therapeutics, Sensei bolstered its oncology pipeline, with PIKTOR designed as an all-oral drug combination that simultaneously inhibits PI3K-alpha and mTORC1/2, which is anticipated to improve efficacy and tolerability, further solidifying the company's position in the cancer treatment market.
- Stock Price Reaction: Shares of Sensei surged over 200% following the acquisition announcement, reaching their highest level since May 2024 and recording the largest intraday gains in history, indicating strong market confidence in its drug development prospects.
- Market Sentiment Shift: On Stocktwits, retail sentiment flipped from 'bearish' to 'extremely bullish', with many users predicting further stock price increases, reflecting optimistic expectations for Sensei's future performance and driving heightened trading activity.
See More
U.S. Stocks Rise, Nasdaq Gains Over 1%
- Market Performance: U.S. stocks broadly rose on Wednesday, with the Nasdaq Composite gaining over 1% and the Dow up 0.57% to close at 49,814.98, indicating positive market sentiment and increased investor confidence.
- Sector Dynamics: Energy stocks rose by 1.6% on Wednesday, reflecting optimistic expectations for energy demand, while real estate stocks fell by 1.2% on Tuesday, highlighting challenges faced by the sector amid market uncertainties.
- Durable Goods Orders: U.S. durable goods orders fell by 1.4% month-over-month in December, contrasting sharply with a revised 5.4% gain in November, suggesting a potential slowdown in economic growth that could impact future consumer and investment decisions.
- Commodity Markets: Oil prices increased by 4.2% to $64.93 per barrel, gold rose by 2.3% to $5,020.40, and silver climbed 6.2% to $78.120, indicating a rising demand for commodities as investors seek safe-haven assets.
See More
Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M
- Stock Surge: Shares of Sensei Biotherapeutics (SNSE) surged on Wednesday following the announcement of its acquisition of cancer drug developer Faeth Therapeutics, reflecting strong market confidence in the deal and boosting investor sentiment.
- Acquisition Details: The acquisition adds Faeth's oral cancer therapy PIKTOR to Sensei's pipeline, which is expected to provide new revenue growth opportunities for the company, particularly in the competitive cancer treatment market.
- Funding Strategy: Concurrently, the company announced a private placement seeking approximately $200 million through the issuance of Series B non-voting convertible preferred stock, with major investors including RA Capital Management, ensuring robust funding for future R&D initiatives.
- R&D Advancement: Sensei plans to utilize the proceeds to advance PIKTOR through multiple catalysts expected by year-end, including a topline readout from a mid-stage trial in endometrial cancer and the initiation of an early-stage trial in breast cancer, demonstrating the company's strategic focus in oncology.
See More
U.S. Stocks Rise in Morning Trading, Dow Up Approximately 100 Points
- Market Performance: U.S. stocks opened higher on Wednesday, with the Dow Jones index gaining approximately 100 points, or 0.21%, reaching 49,637.82, indicating positive market sentiment.
- Sector Dynamics: Energy shares rose by 1.3% on Wednesday, while real estate stocks fell by 0.8%, reflecting a divergence in performance across different sectors.
- Company Earnings: Analog Devices Inc reported first-quarter earnings of $2.46 per share, exceeding analyst expectations of $2.31, with quarterly sales of $3.16 billion also surpassing the forecast of $3.117 billion, showcasing the company's strong financial performance.
- Commodity Markets: On Wednesday, oil prices increased by 2.9% to $64.13 per barrel, gold rose by 1.8% to $4,994.30, and silver climbed 5% to $77.235, indicating heightened activity in the commodities market.
See More
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
- Coherus Performance: Coherus Oncology, Inc. (CHRS) rose 9.09% in after-hours trading, closing at $1.73 with a $0.14 gain, indicating strong investor confidence in its future prospects.
- Sensei Biotech Surge: Sensei Biotherapeutics, Inc. (SNSE) surged 10.06% after hours, finishing at $12.47 with a $1.14 increase, reflecting positive market expectations for its products.
- uniQure Significant Jump: uniQure N.V. (QURE) posted a 9.96% rise in after-hours trading, closing at $24.95 with a $2.26 gain, suggesting investor optimism regarding its R&D progress.
- IO Biotech Strategic Exploration: Although IO Biotech, Inc. (IOBT) had no fresh news on Thursday, its stock still gained 4.19%, closing at $0.50, indicating market interest in its exploration of strategic alternatives, including potential mergers or asset sales.
See More
